Top-line Results from evoke and evoke+: Two Phase 3, Randomized, Placebo-controlled Trials of Semaglutide in Participants with Early-stage Symptomatic Alzheimer’s Disease (P6-12.006)

We only have this paper's title and publication details.

Randomized trial assesses safety and efficacy of semaglutide in early-stage Alzheimer’s disease, suggesting potential benefits.